Search results for "endpoint"

showing 10 items of 437 documents

Endarterectomy Versus Angioplasty in Patients with Symptomatic Severe Carotid Stenosis (EVA-3S) trial: results up to 4 years from a randomised, multi…

2008

Summary Background Carotid stenting is a potential alternative to carotid endarterectomy but whether this technique is as safe as surgery and whether the long-term protection against stroke is similar to that of surgery are unclear. We previously reported that in patients in the Endarterectomy Versus Angioplasty in Patients with Symptomatic Severe Carotid Stenosis (EVA-3S) trial, the rate of any stroke or death within 30 days after the procedure was higher with stenting than with endarterectomy. We now report the results up to 4 years. Methods In this follow-up study of a multicentre, randomised, open, assessor-blinded, non-inferiority trial, we compared outcome after stenting with outcome …

AdultMalemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentCarotid endarterectomyRisk AssessmentSeverity of Illness IndexFunctional LateralityDouble-Blind MethodRisk FactorsInternal medicineAngioplastyClinical endpointConfidence IntervalsMedicineHumansCarotid StenosisLife Tablescardiovascular diseasesLongitudinal StudiesStrokeEndarterectomyAgedProportional Hazards ModelsRetrospective StudiesEndarterectomy Carotidbusiness.industryHazard ratioAngioplastyMiddle Agedmedicine.diseaseSurgeryStrokeStenosisTreatment OutcomeCardiologyFemaleNeurology (clinical)Carotid stentingbusinessThe Lancet. Neurology
researchProduct

Benefits of skeletal-muscle exercise training in pulmonary arterial hypertension: The WHOLEi + 12 trial

2017

Pulmonary arterial hypertension is often associated with skeletal-muscle weakness. The purpose of this randomized controlled trial was to determine the effects of an 8-week intervention combining muscle resistance, aerobic and inspiratory pressure-load exercises on upper/lower-body muscle power and other functional variables in patients with this disease. Participants were allocated to a control (standard care) or intervention (exercise) group (n = 20 each, 45 ± 12 and 46 ± 11 years, 60% women and 10% patients with chronic thromboembolic pulmonary hypertension per group). The intervention included five, three and six supervised (inhospital) sessions/week of aerobic, resistance and inspirato…

AdultMalemedicine.medical_specialtyWeaknessAdolescentHypertension Pulmonary030204 cardiovascular system & hematologyBreathing ExercisesBench presslaw.inventionYoung Adult03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicineClinical endpointHumansMedicineLeg pressExerciseAgedRetrospective StudiesExercise Tolerancebusiness.industryVO2 maxSkeletal muscleResistance TrainingMiddle AgedAparato respiratorioRespiratory Musclesmedicine.anatomical_structure030228 respiratory systemQuality of LifePhysical therapyCardiologyFemaleAnalysis of variancemedicine.symptomCardiology and Cardiovascular MedicinebusinessHipertensión pulmonarPulmones - Enfermedades
researchProduct

Randomized clinical trial of pancreaticogastrostomy versus pancreaticojejunostomy on the rate and severity of pancreatic fistula after pancreaticoduo…

2013

Abstract Background Anastomotic leakage of pancreaticojejunostomy (PJ) remains the single most important source of morbidity after pancreaticoduodenectomy (PD). The primary aim of this randomized clinical trial comparing PG with PJ after PD was to test the hypothesis that invaginated PG would result in a lower rate and severity of pancreatic fistula. Methods Patients undergoing PD were randomized to receive either a duct-to-duct PJ or a double-layer invaginated PG. The primary endpoint was the rate of pancreatic fistula, using the definition of the International Study Group on Pancreatic Fistula. Secondary endpoints were the evaluation of severe abdominal complications (Clavien–Dindo grade …

AdultMalemedicine.medical_specialtymedicine.medical_treatmentGastroenterologyPancreaticoduodenectomylaw.inventionPancreatic FistulaPancreatectomyPostoperative ComplicationsRandomized controlled triallawInternal medicinemedicineClinical endpointHumansProspective StudiesProspective cohort studyAgedAged 80 and overGastrostomybusiness.industryIncidence (epidemiology)Length of StayMiddle Agedmedicine.diseasePancreaticoduodenectomyGastrostomySurgeryTreatment OutcomePancreatic fistulaPancreatectomyDrainageFemaleSurgerybusinessBritish Journal of Surgery
researchProduct

How to Handle Arterial Conduits in Liver Transplantation? Evidence From the First Multicenter Risk Analysis

2020

OBJECTIVE: The aims of the present study were to identify independent risk factors for conduit occlusion, compare outcomes of different AC placement sites, and investigate whether postoperative platelet antiaggregation is protective. BACKGROUND: Arterial conduits (AC) in liver transplantation (LT) offer an effective rescue option when regular arterial graft revascularization is not feasible. However, the role of the conduit placement site and postoperative antiaggregation is insufficiently answered in the literature. STUDY DESIGN: This is an international, multicenter cohort study of adult deceased donor LT requiring AC. The study included 14 LT centers and covered the period from January 2…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentLiver transplantationRevascularizationRisk Assessment03 medical and health sciences0302 clinical medicineRisk FactorsLTOcclusionmedicineClinical endpointHumansAorta AbdominalVascular Patencybusiness.industryAnastomosis SurgicalGraft SurvivalAnticoagulantsThrombosisPerioperativeMiddle AgedArterial occlusionSurgeryLiver TransplantationRegimenLiver030220 oncology & carcinogenesis030211 gastroenterology & hepatologySurgeryFemalebusinessVascular Surgical ProceduresCohort study
researchProduct

Activity and safety of temozolomide in advanced adrenocortical carcinoma patients

2019

Objective Temozolomide has shown a significant anti-proliferative activity on adrenocortical cancer (ACC) cells in vitro. Design On the basis of these results the drug was prescribed as second/third line in advanced metastatic ACC patients in four referral centers in Italy. Methods We retrospectively collected anagraphic, clinical and pathological data of patients with advanced ACC with disease progression to standard chemotherapy plus mitotane who were treated with temozolomide at the dose of 200 mg/m2/die given for 5 consecutive days every 28 days. The primary endpoint was the disease control rate, defined as objective response or disease stabilization after 3 months. Secondary endpoints…

AdultOncologymedicine.medical_specialtytemozolomide adrenocortical carcinomaDisease ResponseSettore MED/06 - Oncologia MedicaEndocrinology Diabetes and Metabolismmedicine.medical_treatment030209 endocrinology & metabolism03 medical and health sciences0302 clinical medicineEndocrinologyStable DiseaseInternal medicineAdrenocortical CarcinomaTemozolomideClinical endpointHumansMedicineAdrenocortical carcinomaMitotaneDNA Modification MethylasesAgedRetrospective StudiesChemotherapyTemozolomidebusiness.industryTumor Suppressor ProteinsRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseaseDNA Repair EnzymesEndocrinology030220 oncology & carcinogenesisbusinessmedicine.drug
researchProduct

SQ HDM SLIT-tablet (ALK) in treatment of asthma – Post hoc results from a randomised trial

2014

SummaryIntroductionIn a double-blind, placebo-controlled trial (EudraCT identifier: 2006-001795-20), the standardised quality (SQ) house dust mite (HDM) sublingual immunotherapy (SLIT)-tablet (ALK, Denmark) was investigated.MethodThe trial included 604 subjects, ≥14 years, with mild-moderate HDM allergic asthma. Subjects were randomised 1:1:1:1 to 1, 3 or 6 SQ-HDM or placebo once daily. The primary endpoint was reduction in inhaled corticosteroid (ICS) after one year. ICS reduction, asthma quality of life questionnaire (AQLQ) and asthma control questionnaire (ACQ) score was analysed post hoc in a subgroup with daily ICS use of 400–800 μg and ACQ score of 1–1.5, corresponding to partly contr…

AdultPulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtymedicine.drug_classPopulationPlaceboHouse dust miteDouble-Blind MethodQuality of lifeSurveys and QuestionnairesmedicineClinical endpointAnimalsHumansSLIT-tabletBudesonideeducationGlucocorticoidsICS reductionAsthmaHouse dust miteSublingual Immunotherapyeducation.field_of_studybiologybusiness.industryPyroglyphidaemedicine.diseasebiology.organism_classificationAsthma; Asthma quality of life; House dust mite; ICS reduction; SLIT-tabletAsthmaTreatment OutcomeAsthma Control QuestionnaireQuality of LifeCorticosteroidAsthma quality of lifebusinessTabletsRespiratory Medicine
researchProduct

Omalizumab (Xolair®) improves quality of life in adult patients with allergic asthma: a review

2003

Abstract Physicians are increasingly aware that asthma causes significant impairment of the patient's physical, psychological, and social well-being. Whilst standard clinical endpoints provide significant information on airway status during treatment, it is important to determine whether such improvements overcome the functional impairment that patients have to deal with on a daily basis. As such, assessment of health-related quality of life (QoL) is an important aspect of asthma management in clinical practice. Omalizumab (Xolair ® ) is a recombinant humanized monoclonal anti-immunoglobulin E (IgE) antibody that represents a new therapeutic approach to IgE-mediated diseases such as allergi…

AdultPulmonary and Respiratory Medicinemedicine.medical_specialtyAdolescentOmalizumabAntibodies Monoclonal HumanizedImmunoglobulin EPlaceboTherapeutic approachDouble-Blind MethodQuality of lifeInternal medicinemedicineClinical endpointHumansAnti-Asthmatic Agentsanti-IgEChildquality of life.AgedAsthmabiologybusiness.industryRespiratory diseaseAntibodies MonoclonalMiddle Agedmedicine.diseaseAsthmaAntibodies Anti-IdiotypicQuality of Lifebiology.proteinPhysical therapyomalizumabbusinessAttitude to Healthallergic asthmamedicine.drugRespiratory Medicine
researchProduct

Effects of anemia correction with epoetin beta in patients receiving radiochemotherapy for advanced cervical cancer

2007

Patients with cervical cancer frequently suffer from anemia. This two-stage, adaptive-design study investigated the effect of anemia correction with epoetin beta on treatment outcomes. Patients with stage IIB–IVA cervical cancer received radiochemotherapy (RCT) and were randomized to epoetin 150 IU/kg three times weekly (n = 34) or standard care (control; n = 40) for up to 12 weeks. Primary end point for stage 1 aimed to establish a correlation between anemia correction and treatment failure (no complete response or relapsing within 6 months after RCT initiation) as a proof of concept before moving into stage 2. Secondary end points included progression/relapse-free survival, overall surviv…

Adultmedicine.medical_specialtyAnemiaInjections Subcutaneousmedicine.medical_treatmentUterine Cervical NeoplasmsRisk AssessmentGastroenterologyDrug Administration Schedulelaw.inventionRandomized controlled trialReference ValueslawInternal medicinemedicineClinical endpointHumansAdverse effectErythropoietinSurvival analysisNeoplasm StagingProbabilityCervical cancerChemotherapyEpoetin betaDose-Response Relationship Drugbusiness.industryObstetrics and GynecologyAnemiaMiddle Agedmedicine.diseaseCombined Modality TherapyImmunohistochemistrySurvival AnalysisRecombinant ProteinsSurgeryLogistic ModelsTreatment OutcomeOncologyChemotherapy AdjuvantFemaleRadiotherapy AdjuvantbusinessFollow-Up StudiesInternational Journal of Gynecologic Cancer
researchProduct

A European Study of the Performance and Safety of MINIject in Patients With Medically Uncontrolled Open-angle Glaucoma (STAR-II)

2020

Precis In this European study (STAR-II), MINIject, a novel, ab-interno, supraciliary MIGS device, effectively lowered intraocular pressure (IOP) and the need for IOP-lowering medications in patients with primary open-angle glaucoma. Purpose To evaluate the safety and performance of a minimally invasive supraciliary glaucoma drainage device (MINIject DO627, iSTAR Medical SA, Wavre, Belgium) for surgical treatment of primary open angle glaucoma in patients refractory to topical hypotensive medications. Methods In a prospective, interventional, single-arm, multi-center, European study (STAR-II), MINIject was successfully implanted in a standalone procedure in 29 of 31 patients in 8 sites in 3 …

Adultmedicine.medical_specialtyIntraocular pressureTime Factorsgenetic structuresOpen angle glaucomaGlaucomaOriginal StudiesProsthesis ImplantationTonometry Ocular03 medical and health sciences0302 clinical medicineRefractoryOphthalmologymedicineClinical endpointHumansMinimally Invasive Surgical ProceduresSingle-Blind MethodIn patientEuropean UnionProspective StudiesGlaucoma Drainage ImplantsAdverse effectAntihypertensive AgentsIntraocular PressureAgedAged 80 and overEquipment Safetybusiness.industryIOPMIGSMiddle Agedmedicine.diseaseGlaucoma drainage deviceMINIjecteye diseasesOphthalmologyglaucomaTreatment Outcome030221 ophthalmology & optometryFemalesupraciliarysense organsbusinessGlaucoma Open-Angle030217 neurology & neurosurgeryJournal of Glaucoma
researchProduct

Influence of Early versus Late supplemental ParenteraL Nutrition on long-term quality of life in ICU patients after gastrointestinal oncological surg…

2019

Abstract Background Nutrition plays a major role in intensive care unit (ICU) treatment, influencing ICU length of stay and patient’s survival. If preferable enteral nutrition administration is not feasible, ESPEN and ASPEN guidelines recommend initiation of a supplemental parenteral route between the first and seventh day, but exact timing remains elusive. While rapid development in critical care enabled significant reduction in the mortality rate of ICU patients, this improvement also tripled the number of patients going to rehabilitation. Thus, it is quality of life after ICU that has become the subject of interest of clinicians and healthcare policy-makers. A growing body of evidence in…

Adultmedicine.medical_specialtyParenteral NutritionCritical IllnessPopulationMedicine (miscellaneous)law.inventionTime03 medical and health sciencesStudy Protocol0302 clinical medicineQuality of lifeRandomized controlled triallawEarly Medical InterventionClinical endpointMedicineHumansSupplemental parenteral nutritioncancergastrointestinal surgeryPharmacology (medical)030212 general & internal medicineeducationWastingDigestive System Surgical ProceduresGastrointestinal NeoplasmsRandomized Controlled Trials as TopicPostoperative Carelcsh:R5-920education.field_of_studybusiness.industryMortality rate030208 emergency & critical care medicineIntensive care unitIntensive Care UnitsParenteral nutritionquality of lifeEmergency medicineDietary SupplementsICUmedicine.symptomlcsh:Medicine (General)businessproteinTrials
researchProduct